COVID-19 is a serious health concern and the impact on our lives continues to evolve on a daily basis. In these unprecedented times, individuals with pre-existing conditions need to be especially careful. With the distribution of the Pfizer-19 vaccine under way in Canada, many of those affected by PKD have questions. It is our goal to provide you with up-to-date information as it relates to this virus, the vaccine, and to help ease your mind during this challenging time.
The PKD Foundation of Canada is proud to present this complimentary webinar, “Polycystic Kidney Disease & the Pfizer-BioNTech COVID-19 Vaccine.” This webinar will give you the opportunity to ask questions to nephrologist and PKD specialist, Dr. Daniel G. Bichet. We hope you can join us!
When: Wednesday, February 17th 7:00-9:00pm EST
Speaker: Daniel G. Bichet, MD
About the Speaker: Dr. Daniel G. Bichet
Daniel G. Bichet, MD is Professor of Medicine, Pharmacology and Physiology at the Université de Montréal and a staff nephrologist at the Hôpital du Sacré-Coeur de Montréal. He obtained his medical degree at the Université de Besançon (France) and completed additional clinical training at the Hôtel-Dieu de Montréal Hospital (Université de Montréal), Montréal General Hospital, and Royal Victoria Hospital (McGill University). He did a research fellowship at the University of Colorado Health Sciences Center under the mentorship of Dr. Robert Schrier with the encouragements of Dr Julien Marc-Aurèle in Montreal.
Dr. Bichet obtained a CIHR Chair in Genetics of Renal Diseases from 2003 to 2010. He received the Jonathan Ballon Award of the Quebec Heart and Stroke Foundation, was a scholar of the Heart and Stroke Foundation of Canada and le Fonds de la recherche en santé du Québec (FRSQ). He was also a recipient of a Career Investigator Award of the FRSQ. Dr. Bichet’s research includes fundamental life-sustaining homeostatic networks for water and osmotic pressure balance in human physiology. His laboratory is contributing to the prevention of extreme dehydration states in children with polyuric disorders (Nephrogenic Diabetes Insipidus), and received a related grant from the Canadian Gene Cure Foundation.
Dr. Bichet received the Medal of the Kidney Foundation of Canada in 1998, a Doctorat Honoris Causa from the University of Nancy (France) in 1999, and the Jean Hamburger Medal (the highest distinction of the European Society of Nephrology) in 2010. His laboratory reconstructed and sequenced more than 50 independent families from Québec with Autosomal Dominant Kidney Disease and many of these patients are now receiving tolvaptan, a vasopressin V2 receptor antagonist.
For more information on COVID-19 and the Pfizer-BioNTech COVID-19 Vaccine, visit the Government of Canada’s website here.